Commentary

A New Target for Anti-HIV Strategies

Published in Vaccine Weekly, April 24th, 1995

A unique regulatory protein may be the Achilles heel of HIV, a series of new studies suggests.

Several separate laboratories are racing to develop novel drugs, vaccines and gene therapies that take advantage of these findings.

The new research shows that the protein, viral protein R (Vpr), may be far more important in HIV infectivity and pathogenesis than previously had been thought. If Vpr is indeed essential for HIV to cause AIDS, it will be an attractive target for intervention: unlike the viral proteins targeted by current AIDS therapies and HIV vaccines, Vpr is one of the most highly conserved HIV-1 proteins.

Vpr is the...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (1995-04-24)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry